Advanced SCAC: Disease Burden and Historical Treatment Challenges

In this opening segment, Dr. Marwan Fakih and Dr. Richard Kim outline the current epidemiology, biology, and therapeutic challenges associated with advanced squamous cell carcinoma of the anal canal (SCAC). Although SCAC remains a relatively rare malignancy, with approximately 10,000 new cases annually in the United States, its incidence has been steadily increasing. Patients often present with symptoms such as rectal pain and bleeding, which can significantly affect quality of life.

From a biologic perspective, the disease is predominantly driven by human papillomavirus (HPV), which is implicated in roughly 90% of cases. Although SCAC was historically associated with HIV/AIDS, improved management of HIV has shifted the primary etiologic focus toward HPV infection. This viral association has important implications for prevention strategies and provides a biologic rationale for the use of immunotherapy.

Despite these insights, advanced disease remains difficult to manage. Most patients present with localized or regional disease and can be cured with chemoradiation. However, metastatic disease represents a smaller but clinically significant population with limited therapeutic options and historically poor durability of response. The rarity of advanced SCAC has also hindered drug development, making it challenging to conduct large randomized trials.

As a result, treatment standards have historically relied on limited evidence. The previous first-line standard (carboplatin plus paclitaxel) was supported primarily by randomized phase 2 data rather than definitive phase 3 trials. This lack of high-level evidence has contributed to a longstanding unmet need for more effective, evidence-based therapies in advanced SCAC, setting the stage for recent advances in the field.